Assessing the quality and value of quality-of-life measurement in breast cancer clinical trials

Journal of the National Cancer Institute

Volumn 103, Issue 3, 2011, Pages 196-199

  Ganz, Patricia A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; HORMONAL THERAPY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 79551691691     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq542     Document Type: Article

References (28)

1. Priestman TJ, Baum M.Evaluation of quality of life in patients receiving treatment for advanced breast cancer.Lancet. 1976; 1 ( 7965 ): 899-900.
2. Berry DA, Cronin KA, Plevritis SK, et al.Effect of screening and adjuvant therapy on mortality from breast cancer.N Engl J Med. 2005; 353 ( 17 ): 1784-1792. (Pubitemid 41549890)
3. Lipscomb J, Gotay CC, Snyder C.Outcomes Assessment in Cancer.Cambridge, UK : Cambridge University Press; 2005.
4. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA.Health-related quality-oflife measurement in randomized clinical trials in breast cancer-taking stock.J Natl Cancer Inst. 2003; 95 ( 4 ): 263-281. (Pubitemid 36336477)
5. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V.Qualityof-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).J Natl Cancer Inst. 2010; 103 ( 3 ): 178-231.
6. Guidance for Industry, Patient Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims [Online].: US Department of Health and Human Services, Food and Drug Administration; 2009.http :// www. fda.gov / downloads / Drugs / GuidanceComplianceRegulatoryInformation / Guidances / UCM193282.pdf.Accessed November 23, 2010.
7. Sloan J, Frost M, Berzon R, et al.The clinical signifi cance of quality of life assessments in oncology: a summary for clinicians.Support Care Cancer. 2006; 14 ( 10 ): 988-998. (Pubitemid 44451304)
8. Bernhard J, Cella DF, Coates AS, et al.Missing quality of life data in cancer clinical trials: serious problems and challenges.Stat Med. 1998; 17 ( 5-7 ): 517-532. (Pubitemid 28118924)
9. Clauser SB, Ganz PA, Lipscomb J, Reeve BB.Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making.J Clin Oncol. 2007; 25 ( 32 ): 5049-5050. (Pubitemid 350232282)
10. Ganz PA, Gotay CC.Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions.J Clin Oncol. 2007; 25 ( 32 ): 5063-5069. (Pubitemid 350232284)
11. Lipscomb J, Reeve BB, Clauser SB, et al.Patient-reported outcomes assessment in cancer trials: taking stock, moving forward.J Clin Oncol. 2007; 25 ( 32 ): 5133-5140. (Pubitemid 350232295)
12. Sprangers MA, Groenvold M, Arraras JI, et al.The European Organization for Research and Treatment of Cancer breast cancer-specifi c quality-oflife questionnaire module: fi rst results from a three-country fi eld study.J Clin Oncol. 1996; 14 ( 10 ): 2756-2768. (Pubitemid 26329662)
13. Brady MJ, Cella DF, Mo F, et al.Reliability and validity of the functional assessment of cancer therapy -breast quality-of-life instrument.J Clin Oncol. 1997; 15 ( 3 ): 974-986. (Pubitemid 27106280)
14. Land SR, Kopec JA, Yothers G, et al.Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: fi ndings from the National Surgical Adjuvant Breast and Bowel Project B-23.Breast Cancer Res Treat. 2004; 86 ( 2 ): 153-164. (Pubitemid 38988018)
15. Cleeland CS, Sloan JA.Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.J Pain Symptom Manage. 2010; 39 ( 6 ): 1077-1085.
16. Basch E.The missing voice of patients in drug-safety reporting.N Engl J Med. 2010; 362 ( 10 ): 865-869.
17. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR.Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.J Clin Oncol. 2000; 18 ( 4 ): 743-753. (Pubitemid 30106604)
18. Bower JE.Behavioral symptoms in patients with breast cancer and survivors.J Clin Oncol. 2008; 26 ( 5 ): 768-777. (Pubitemid 351264390)
19. Castellon SA, Ganz PA, Bower JE, Petersen LA, Abraham L, Greendale GA.Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.J Clin Exp Neuropsychol. 2004; 26 ( 7 ): 955-969. (Pubitemid 39577316)
20. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE.Life after breast cancer: understanding women's health-related quality of life and sexual functioning.J Clin Oncol. 1998; 16 ( 2 ): 501-514. (Pubitemid 28135592)
21. Savard J, Simard S, Blanchet J, Ivers H, Morin CM.Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer.Sleep. 2001; 24 ( 5 ): 583-590. (Pubitemid 32660384)
22. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S.Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.J Pain. 2009; 10 ( 11 ): 1146-1150.
23. Ware JE Jr.SF-36 Health Survey. Manual and Interpretation Guide.Boston, MA : The Health Institute, New England Medical Center; 1993.
24. Radloff LS.The CES-D Scale: a self-report depression scale for research in the general population.Appl Psychol Meas. 1977; 1 ( 3 ): 385-401.
25. Ganz PA, Day R, Ware JE Jr., Redmond C, Fisher B.Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial.J Natl Cancer Inst. 1995; 87 ( 18 ): 1372-1382.
26. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B.Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Clin Oncol. 1999; 17 ( 9 ): 2659-2669. (Pubitemid 29415221)
27. Stanton AL, Bernaards CA, Ganz PA.The BCPT Symptom Scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer.J Natl Cancer Inst. 2005; 97 ( 6 ): 448-456. (Pubitemid 40528608)
28. Cella D, Land S, Chang CH, et al.Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women.Breast Cancer Res Treat. 2008; 109 ( 3 ): 515-526. (Pubitemid 351692068)